financetom
Business
financetom
/
Business
/
Arcline-backed Arxis reveals revenue surge in US IPO filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arcline-backed Arxis reveals revenue surge in US IPO filing
Mar 24, 2026 4:06 PM

March 24 (Reuters) - Private equity firm Arcline-backed

Arxis revealed its annual revenue more than doubled in its

filing for a U.S. initial public offering on Tuesday,

underscoring strong sponsor appetite to test the listing market

amid surging demand for aerospace and defense parts.

The filing comes as aerospace and defense companies attract

renewed investor interest, supported by rising global defense

spending and resilient commercial aviation demand.

Arxis, which produces parts such as flight control bearings

and engine fire seals and serves aerospace and defense original

equipment manufacturers, said it had about 5,750 employees as of

December 31, 2025.

Arcline, which specializes in industrial investments and

currently controls Arxis, is expected to remain a long-term

investor in the company following the IPO.

The private equity firm struck a deal with KKR in

November to acquire aerospace and defense hardware maker Novaria

Group for $2.2 billion.

Arxis reported a net income of about $46 million on revenue

of $1.59 billion in 2025, compared with a loss of $55.5 million

on revenue of $743 million in 2024.

The company said it has applied to list its stock on the

Nasdaq exchange under the symbol "ARXS."

Goldman Sachs, Morgan Stanley and Jefferies were among the

joint bookrunning managers for the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved